| 23-Dec-10 |
| Aurobindo Pharma Ltd has informed BSE that an Extra Ordinary General Meeting (EGM) of the members of the Company will be held on December 23, 2010, inter alia, to Sub-division of 13,20,00,000 Equity Shares of the face value of Rs. 5/- each in the Authorised Share Capital of the Company into 66,00,00,000 Equity Shares of the face value of Rs. 1/- each.
Further to resolve that the existing Clause V of the Memorandum of Association of the Company relating to share capital be altered by deleting the same and substituting in place thereof the following new Clause V.
'V. a) The Authorised Share Capital of the Company is Rs. 76,00,00,000/- (Rupees Seventy Six Crores only) divided into 66,00,00,000 (Sixty Six Crores only) Equity Shares of Re.1/- (Rupee One only) each and 10,00,000 (Ten Lakhs only) Preference Shares of Rs. 100/- (Rupees One Hundred only) each.
b) The Company has power from time to time increase in Capital as Equity or preferred Shares and to attach to any class or classes of such Shares, preferences, rights, privileges or priorities in payment of dividends, or distribution of assets, or otherwise over and other shares and to subject the same to any restrictions, limitations or conditions and to vary the regulations of the Company, as to a portion the right to participate in profits in any manner subject to the prior consent of the Government of India or the order of the court, if the same will be necessary being obtained before doing so.
Further to resolve that the existing Article 3 of the Articles of Association of the Company relating to share capital be altered by deleting the same and substituting in place thereof the following new Article 3.
'3. The Authorised Share Capital of the Company is Rs. 76,00,00,000/- (Rupees Seventy Six Crores only) divided into 66,00,00,000 (Sixty Six Crores only) Equity Shares of Re. 1/- (Rupee One only) each and 10,00,000 (Ten Lakhs only) Preference Shares of Rs. 100/- (Rupees One Hundred only) each and the same may be increased or reduced in accordance with the Companies Act, 1956 and the Memorandum of Association as and when thought fit by the Board of Directors.'
Aurobindo Pharma Ltd has informed BSE that the shareholders at the Extraordinary General Meeting (EGM) of the Company held on December 23, 2010, have approved the sub-division of one equity share of the face value of Rs. 5/-each in the Company into five equity shares of the face value of Rs. 1/- each.
Aurobindo Pharma Ltd has submitted to BSE a copy of extract of the minutes of the Extra Ordinary General Meeting (EGM) of the Company held on December 23, 2010.
(As Per BSE Announcement Website Dated on 23/12/2010) |
| 20-Jan-10 |
| Aurobindo Pharma Ltd has informed BSE that by an order made on December 09, 2009, the Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad has directed that a Meeting of the Equity Shareholders of the Applicant Company i.e., Aurobindo Pharma Ltd., be convened and held on January 20, 2010, for the purpose of considering and if thought fit approving, with or without modification(s), the Scheme of Amalgamation proposed to be made between Trident Life Sciences Ltd. and Aurobindo Pharma Ltd. and their respective shareholders.
Aurobindo Pharma Ltd has informed BSE that the Shareholders of the Company at their meeting held on January 20, 2010, as per the directions of the Hon'ble High Court of Andhra Pradesh at Hyderabad, have approved the Scheme of Amalgamation between Trident Life Sciences Ltd. (a wholly owned subsidiary of Aurobindo Pharma Ltd.) and Aurobindo Pharma Ltd and their respective Shareholders.
(As Per BSE Announcement Website dated on 21.01.2010) |
| 21-May-09 |
| Aurobindo Pharma Ltd has informed the Exchange that by an order made on April 18, 2009 in the Company Application, the Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad has directed that a Meeting of the Equity Shareholders
of the Applicant Company i.e., Aurobindo Pharma Limited, be convened and held on May 21, 2009 for the purpose of considering and if thought fit approving, with or without modification(s), the arrangements embodied in the Scheme of Arrangement proposed to be made between Aurobindo Pharma Limited and its Shareholders.
Aurobindo Pharma Ltd has informed BSE that the Shareholders of the Company at its meeting held on May 21, 2009, as per the directions of the Hon'ble High Court of Andhra Pradesh at Hyderabad, have approved the Scheme of Arrangement between the Company and its Shareholders by requisite majority.
The Shareholders have also approved the resolution for the reduction of capital in the form of utilization of Capital Redemption Reserve Account as the proposed Scheme involves Utilization of the Capital Redemption Reserve Account and creation of Reconstruction Reserve Account.
(As Per BSE Announcement Website dated on 22.05.2009) |
| 20-Feb-07 |
| Aurobindo Pharma Ltd has informed BSE that pursuant to the order made by the High Court of Judicature of Andhra Pradesh, at Hyderabad, a meeting of the Equity Shareholders of the Company will be held on February 20, 2007, for the purpose of considering, and if thought fit, approving with or without modification(s), the arrangement embodied in the Scheme of Arrangement proposed to be made between the Company and APL Life Sciences Ltd and Senor Organics Pvt Ltd |
| 27-Apr-06 |
| Board has considered and approved the proposal to issue Foreign Currency Convertible Bonds (FCCBs) up to USD 200 million in overseas markets to fund
amongst other things, the overseas acquisitions and future growth requirements of the Company.
Further, it has been decided to convene an Extra Ordinary General Meeting (EGM) of the members of the Company on April 27, 2006 to seek their approval
EGM 27/04/2006
inter alia, to transact the following business:
1. To create, offer, issue and allot from time to time to all eligible investors, whether members
of the Company or not, through a public issue and / or on a private placement basis, Ordinary
Shares, debentures whether partly / fully convertible, and/or Securities linked to Ordinary
Shares and / or foreign currency convertible bonds convertible into Equity shares or depository receipts and / or Securities convertible into equity shares at the option of the Company and / or the holder of such Securities and / or equity shares through depository receipts ("Securities"), through prospectus and / or offer letter so however that the total amount raised through the aforesaid Securities do not exceed US$ 200 Million, such issue and allotment to be made at such time or times, in one or more tranches, at such price or prices, in such manner, subject to necessary approvals & provisions.
2. To borrow periodically from, including without limitation, any Banks and / or public financial institutions as defined under Section 4 of the Companies Act, 1956 and / or any foreign financial institution(s) and / or any entity / entities or authority / authorities and / or through suppliers credit Securities instruments, such as floating rate notes, fixed rate notes, syndicated loans, debentures, commercial papers, short term loans or any other instruments, etc and / or through credit from official agencies and / or by way of commercial borrowings from the private sector window of multilateral financial institution(s), either in rupees or in such other foreign currencies as may be permitted by law from time to time, as may be deemed appropriate by the Board for an aggregate amount not exceeding Rs 30,000 million notwithstanding, that money so borrowed together with the monies already borrowed by the
Company, if any (apart from temporary loans obtained from the Company's bankers in the
ordinary course of business) may exceed the aggregate of the paid up capital of the Company
and its free reserves, that is to say, reserves not set apart for any specified purpose, subject
to necessary approvals & provisions.
3. For mortgaging and / or charging on such terms and conditions for borrowing upto Rs 30,000 million at such time or times and from time to time and in such form or manner, as they
may think fit, the whole or substantially the whole of the Company's any one or more of the
undertakings including the present and / or future properties, whether movable or immovable
comprised in any or new undertaking(s) of the Company as the case may be, in favour of
financial institutions, corporations, banks, mutual funds, government / other agencies or any
other person(s), entities which give, provide or extend loans / facilities to the Company or in
favour of trustees of such lenders to secure the said amount of loans / debentures together
with interest thereon, commitment charges, liquidated damages, premium on redemption,
trustees remuneration, costs, charges, expenses and all other moneys payable under the
agreement(s) / arrangement(s) entered into / to be entered into by the Company in respect of
the said loans as the Board may deem fit in the best interests of the Company, subject to
necessary approvals & provisions.
(As per BSE Bulletin dated on 04/04/2006)
Aurobindo Pharma Ltd has informed the Exchange that in the Extra Ordinary General meeting of the
members of the Company held on April 27, 2006 the members approved the special resolution for issue of Foreign Currency Convertible Bonds (FCCBs) up to USD 200 million in overseas markets to fund amongst other things, the overseas acquisitions and future growth requirements of the Company. The Company has now informed further that the members approved the ordinary resolutions to increase the borrowing powers of the Directors from the existing limit of Rs.1500 Crores to Rs.3000 Crores in terms of Section 293(1) (d) and to mortgage and charge for borrowings upto Rs.3000 Crores u/s.293(1) (a) of the Companies Act, 1956.
(As per NSE bulletin dated on 28/04/2006)
Aurobindo Pharma Ltd has informed BSE that members at the Extra Ordinary General Meeting(EGM) of the Company held on April 27, 2006, inter alia, have approved the following resolutions: 1. Issue of Foreign Currency Convertible Bonds (FCCBs) upto
USD 200 Million in overseas markets to fund amongst other things, the overseas acquisitions and future growth requirements of the Company. 2. To Increase the borrowing powers of Directors from the existing limit of Rs 15000 million to Rs 30000
million. 3. To mortgage and charge for borrowings upto Rs 30000 million.
(As per BSE Bulletin dated on 28/04/2006)
Aurobindo Pharma Ltd has submitted to the Exchange a copy of the proceedings of the
Extraordinary General Meeting of the members of the Company held on April 27, 2006.
(As per NSE Bulletin dated on 03/05/2006) |